RU2232594C2 - Комплекс, содержащий ингибирующий остеокластогенез фактор (ocif) и полисахарид - Google Patents

Комплекс, содержащий ингибирующий остеокластогенез фактор (ocif) и полисахарид Download PDF

Info

Publication number
RU2232594C2
RU2232594C2 RU2002117385/15A RU2002117385A RU2232594C2 RU 2232594 C2 RU2232594 C2 RU 2232594C2 RU 2002117385/15 A RU2002117385/15 A RU 2002117385/15A RU 2002117385 A RU2002117385 A RU 2002117385A RU 2232594 C2 RU2232594 C2 RU 2232594C2
Authority
RU
Russia
Prior art keywords
ocif
complex
specified
group
variants
Prior art date
Application number
RU2002117385/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002117385A (ru
Inventor
Синити ЯМАМОТО (JP)
Синити ЯМАМОТО
Дзунити ОКАДА (JP)
Дзунити ОКАДА
Ацуси КУРИХАРА (JP)
Ацуси КУРИХАРА
Таку НУМАЗАВА (JP)
Таку НУМАЗАВА
Дзунити КОНДО (JP)
Дзунити КОНДО
Еисуке ЦУДА (JP)
Еисуке ЦУДА
Синити МОТИЗУКИ (JP)
Синити МОТИЗУКИ
Хиротака НИСИ (JP)
Хиротака НИСИ
Хидеки МИЯЗАКИ (JP)
Хидеки МИЯЗАКИ
Original Assignee
Санкио Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани Лимитед filed Critical Санкио Компани Лимитед
Publication of RU2002117385A publication Critical patent/RU2002117385A/ru
Application granted granted Critical
Publication of RU2232594C2 publication Critical patent/RU2232594C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2002117385/15A 2001-06-29 2002-06-28 Комплекс, содержащий ингибирующий остеокластогенез фактор (ocif) и полисахарид RU2232594C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29
JP2001-198985 2001-06-29

Publications (2)

Publication Number Publication Date
RU2002117385A RU2002117385A (ru) 2004-01-27
RU2232594C2 true RU2232594C2 (ru) 2004-07-20

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002117385/15A RU2232594C2 (ru) 2001-06-29 2002-06-28 Комплекс, содержащий ингибирующий остеокластогенез фактор (ocif) и полисахарид

Country Status (22)

Country Link
US (3) US20030045456A1 (fr)
EP (1) EP1270015A3 (fr)
KR (1) KR20030003124A (fr)
CN (1) CN1442201A (fr)
AR (1) AR034716A1 (fr)
AU (1) AU783126B2 (fr)
BR (1) BR0202439A (fr)
CA (1) CA2392383A1 (fr)
CO (1) CO5390084A1 (fr)
CZ (1) CZ20022231A3 (fr)
HK (1) HK1048762A1 (fr)
HU (1) HUP0202119A2 (fr)
IL (1) IL150448A0 (fr)
MX (1) MXPA02006511A (fr)
NO (1) NO20023144L (fr)
PA (1) PA8549401A1 (fr)
PE (1) PE20030254A1 (fr)
PL (1) PL354799A1 (fr)
RU (1) RU2232594C2 (fr)
SG (1) SG98059A1 (fr)
SK (1) SK9492002A3 (fr)
ZA (1) ZA200205164B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2642612C2 (ru) * 2012-07-27 2018-01-25 Альтергон С.А. Комплексы на основе хондроитина для чрескожного всасывания

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
TR200101146T2 (tr) 1998-10-28 2001-09-21 Sankyo Co., Ltd. Kemik-patobolizmasını tedavi edici madde.
EP1270015A3 (fr) * 2001-06-29 2004-02-25 Sankyo Company Limited Un complexe de OCIF et de polysaccharide
EP1482978A1 (fr) * 2002-03-01 2004-12-08 Sankyo Company, Limited Composition pharmaceutique comprenant un facteur inhibiteur de l'osteoclastogenese
CN1658895A (zh) 2002-04-10 2005-08-24 应用研究系统Ars股份公司 护骨素在治疗和／或预防纤维变性疾病中的应用
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2003103710A1 (fr) * 2002-06-07 2003-12-18 三共株式会社 Effets combines d'une composition d'agents preventifs ou therapeutiques sur une fracture osseuse
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207A (en) * 1845-09-27 lewis
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US31725A (en) * 1861-03-19 Improvement in cultivators
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
TW318142B (fr) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
KR100547395B1 (ko) * 1997-09-24 2006-02-01 산쿄 가부시키가이샤 골대사이상증의 진단방법
WO1999065916A1 (fr) * 1998-06-15 1999-12-23 Takeda Chemical Industries, Ltd. Derives de thienodipyridine, production et utilisation
TR200101146T2 (tr) * 1998-10-28 2001-09-21 Sankyo Co., Ltd. Kemik-patobolizmasını tedavi edici madde.
CA2349406C (fr) * 1999-09-03 2011-01-11 Amgen Inc. Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (fr) * 2001-06-29 2004-02-25 Sankyo Company Limited Un complexe de OCIF et de polysaccharide
EP1482978A1 (fr) * 2002-03-01 2004-12-08 Sankyo Company, Limited Composition pharmaceutique comprenant un facteur inhibiteur de l'osteoclastogenese

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RU 2146132 A, l0.03.2000. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2642612C2 (ru) * 2012-07-27 2018-01-25 Альтергон С.А. Комплексы на основе хондроитина для чрескожного всасывания

Also Published As

Publication number Publication date
PA8549401A1 (es) 2003-07-28
AU5071902A (en) 2003-01-02
ZA200205164B (en) 2003-03-24
CN1442201A (zh) 2003-09-17
AU783126B2 (en) 2005-09-29
PE20030254A1 (es) 2003-03-19
CZ20022231A3 (cs) 2003-02-12
KR20030003124A (ko) 2003-01-09
US20030139325A1 (en) 2003-07-24
SK9492002A3 (en) 2003-02-04
HUP0202119A2 (hu) 2003-04-28
US20030045456A1 (en) 2003-03-06
AR034716A1 (es) 2004-03-17
CA2392383A1 (fr) 2002-12-29
CO5390084A1 (es) 2004-04-30
HU0202119D0 (fr) 2002-08-28
HK1048762A1 (zh) 2003-04-17
EP1270015A2 (fr) 2003-01-02
PL354799A1 (en) 2002-12-30
MXPA02006511A (es) 2004-08-11
NO20023144L (no) 2002-12-30
BR0202439A (pt) 2003-06-10
NO20023144D0 (no) 2002-06-28
IL150448A0 (en) 2002-12-01
US20060084595A1 (en) 2006-04-20
SG98059A1 (en) 2003-08-20
EP1270015A3 (fr) 2004-02-25
RU2002117385A (ru) 2004-01-27

Similar Documents

Publication Publication Date Title
US20060084595A1 (en) Complex comprising OCIF and polysaccharide
JP6976859B2 (ja) ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
US5270199A (en) Human mannose-binding protein
JP2006512326A (ja) 心臓疾患におけるエリスロポエチンの新規な使用
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
JPH03506030A (ja) インスリン様成長因子（ｉｇｆ）結合蛋白複合体の酸不安定サブユニット（ａｌｓ）
JP2020147583A (ja) リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
JPH07504886A (ja) 細胞調節因子のインヒビターおよびはん痕形成を予防または緩和する方法
JP2004527242A (ja) ヒスチジンリッチ糖タンパク質
AU673543B2 (en) Method of inhibiting cell proliferation using apolipoprotein E
US20030216297A1 (en) Pharmaceutical composition
JP2002522512A (ja) デキストラン−レプチン結合体、医薬組成物および関連方法
JP2002519303A (ja) 脂質動員性を有する糖タンパク質およびその治療的適用
AU691085B2 (en) Anti-inflammatory CD14 polypeptides
CA2107475A1 (fr) Proteine fixatrice du facteur de croissance apparente a l'insuline isole du tissu osseux humain
JP4716875B2 (ja) 糖鎖欠損型肝細胞増殖因子
IL297258A (en) Methods for the treatment of anemia using the Act-R-2b ligand trap (type iib activin receptor and pedratinib)
JP2004203747A (ja) 破骨細胞形成抑制因子を含有する治療剤
JP4121852B2 (ja) 癌を予防及び／又は治療するためのタンパク質ｅｓｍ−１のアンタゴニスト化合物の使用、及び癌を予防及び／又は治療するための薬剤の製造
JP2004059582A (ja) 骨破壊の治療または予防剤組成物の併用効果
CA2368937A1 (fr) Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux
JP2003160601A (ja) 破骨細胞形成抑制因子を含有する複合体
US6329500B1 (en) Transforming growth factor-β binding site
JP4271075B2 (ja) 消化器官吸収性ポリペプチド
JP2001526540A (ja) Ｈｇｆポリペプチド及び治療におけるその使用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070629